Page 1

VALEO PHARMA ™ Valeo Pharma Reports its Second Quarter 2021 Results and Highlights • Q2-21 record revenues of $ 2.65 million , up 27 % vs Q2-20 and up 42 % over prior quarter • Q3-21 revenues expected to increase by more than 50 % over Q2-21 • Redesca launched in late Q2-21 • Enerzair® Breezhaler® and AtecturaⓇ BreezhalerⓇ commercial shipments commenced following national respiratory sales force deployment • Closing of upsized $ 6.645 million debenture placement Closing of $ 11.5 million bought deal including full exercise of over - allotment MONTREAL , June 29 , 2021 / CNW / - Valeo Pharma Inc. ( CSE : VPH ) ( OTCQB : VPHIF ) ( FSE : VP2 ) ( " Valeo " or the " Company " ) , a Canadian pharmaceutical company , today reported its financial results for the second quarter ended April 30 , 2021 . " Our record second quarter revenues saw growth coming from our existing portfolio along with the first indication of the material impact that our three important product launches will bring . Redesca TM was launched at the end of the second quarter and has quickly become our best selling product with sales expected to accelerate for quarters to come . Subsequent to the quarter end , we launched Enerzair® Breezhaler® and Atectura® Breezhaler® , two innovative asthma therapies . As a result of these launches , we expect third quarter revenues to expand by more than 50 % over our second quarter . " , commented Steve Saviuk , CEO . " Public and Private reimbursement coverage for Redesca , Enerzair and Atectura is on track and is a key component to ensure patient's have access to these important medications . We are making significant additions to our corporate and commercial structure in order to accelerate our growth and properly support the potential of our world class products . With senior talent joining our leadership team and the expansion of our medical and field commercial teams , Valeo is fast positioning itself as a Canadian leader in our defined therapeutic areas " . Commenting on the second quarter 2021 results , Luc Mainville , Senior Vice - President and Chief Financial Officer said , " Our revenues continued to progress well along with our margin expansion as a result of launching several new products over the last year . Our net results reflected the addition of head office positions from the creation of our 2 distinct Business Units , Respiratory and Specialty products as well as the ongoing integration of our growing national sales force dedicated to the significant market potential of Redesca , Enerzair® Breezhaler® and AtecturaⓇ BreezhalerⓇ products . We expect these three transformative products to fuel our growth over the coming years as we continue adding strategic assets to our portfolio to take full advantage of our new corporate structure and commercial platform . " Second Quarter 2021 Financial Results • Revenues were $ 2.65 million for the quarter ended April 30 , 2021 compared to $ 2.1 million for the quarter ended April 30 , 2020 representing a 27 % increase . The increase over the previous